Ocular Therapeutix Inc
NASDAQ:OCUL
Operating Margin
Ocular Therapeutix Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
1.2B USD |
-342%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
710.2B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
369.8B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
209.5B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
182.8B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
161.5B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
195.6B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
133.2B USD |
27%
|
Ocular Therapeutix Inc
Glance View
Ocular Therapeutix Inc., nestled in the bustling biotechnology hub of Bedford, Massachusetts, is forging a new path in the ophthalmic treatment landscape. At its core, the company's mission pivots on the innovation and commercialization of novel therapies that address significant unmet needs in eye care. By leveraging its proprietary hydrogel technology, Ocular Therapeutix has developed a rich pipeline of both drug delivery and ophthalmic surgical products. Its flagship product, DEXTENZA, stands as a beacon of its innovative approach, offering an alternative to traditional drug delivery methods by releasing medication directly to the target site through a bioresorbable hydrogel implant. This targeted drug delivery not only enhances treatment efficacy but also addresses the age-old challenge of patient compliance in eye care, providing a significant competitive advantage in the market. Financially, Ocular Therapeutix develops its sustainability through a multi-pronged strategy that involves direct sales, licensing agreements, and strategic partnerships. Revenue is primarily generated from sales of its marketed products and milestones achieved through partnerships with other pharmaceutical companies. DEXTENZA and the upcoming products from its pipeline continue to chart new territory in securing market share by offering superior clinical outcomes. The company’s innovative technologies also open doors for licensing deals, providing a steady revenue stream as they partner with global firms that recognize the potential of personalized ophthalmic care. By threading together scientific innovation, strategic commercialization, and robust industry partnerships, Ocular Therapeutix positions itself not just as a biotech company, but as a transformative player aiming to redefine the ophthalmic treatment paradigm.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Ocular Therapeutix Inc's most recent financial statements, the company has Operating Margin of -342.2%.
You don't have any saved screeners yet